Extensive mutagenesis has defined distinct functional domains in the HIV-1 matrix domain (MA). In an attempt to more clearly define functions of regions of MA which affect viral entry, we analyzed mutations in the N-terminal basic and the C-terminal helical domains. Deletions of 8-10 amino acid residues of the C-terminal fifth helix of MA resulted in viruses that were only mildly defective in infectivity and fusion. The defect exhibited by these mutations could largely be attributed to a reduction in levels of viral envelope incorporated into mature virions. Truncation of the gp41 cytoplasmic tail (gp41CT) could rescue the phenotype of one of these mutants. In contrast, mutations of multiple basic residues in the N-terminus of MA were severely defective in both infectivity and fusion. While these mutations induce severe envelope incorporation defects, they also result in virus crippled at a post-entry step, since truncation of the gp41CT could not rescue the infectivity defect.
Introduction
The HIV-1 Pr55 Gag polyprotein precursor is the major structural determinant of particle formation. Pr55Gag is sufficient for the assembly and release of non-infectious virus-like particles (VLPs). Proteolytic cleavage of Pr55Gag by the viral protease (PR) produces the mature 17 kD matrix (MA), 24 kD capsid (CA), 7 kD nucleocapsid (NC), and p6 domains.
MA is involved in multiple steps of the HIV-1 replication cycle and mutational analysis has identified several domains within MA which regulate these various functions (Fig. 1A ) (Freed, 1998) . MA is important for both early viral replication events, including entry, as well as late assembly events. MA is involved in viral entry by regulating fusion, especially that of immature particles, with target cell membranes (Murakami et al., 2004; Wyma et al., 2004) . In addition to modulating the un-coating of viral cores post-entry, MA is also a component of both the viral reverse transcription and pre-integration complexes (PIC) (Gallay et al., 1995) . Two proposed nuclear localization sequences in MA may aid in nuclear import of the PIC (Bukrinsky et al., 1993; Haffar et al., 2000) .
MA is necessary for the proper assembly of infectious virions. Export of viral RNA from the nucleus is mediated, in part, by a nuclear export signal in MA (Dupont et al., 1999) . MA also plays a critical role in the membrane binding and targeting of Pr55Gag during assembly. Membrane binding capacity is conferred to the protein by the N-myristylation signal found in the first 6 amino acids (aa) of MA (Bryant and Ratner, 1990; Freed et al., 1994; Spearman et al., 1994) . Targeting to the plasma membrane (PM) or the multivesicular bodies (MVB), from which virions assemble and bud, appears to be at least partially regulated by the concerted actions of the 17 amino acid basic domain (aa 14-31) and aa 80-84 in MA (Freed, 1998; Freed and Martin, 2001; Freed et al., 1994) . Upon synthesis of Pr55 Gag , the myristate moiety (myr) is sequestered by the immature MA domain. Association with lipid raft-associated phosphatidylinositol-(4,5)-bisphosphate (PI(4,5)P 2 ) induces a "myristyl-switch" whereby a subtle conformational change in MA exposes the myr moiety (Ono et al., 2004; Scarlata et al., 1998; Spearman et al., 1997; Tang et al., 2004; Zhou and Resh, 1996) . Exposure of the myr group anchors Pr55 Gag into the lipid rafts. Interactions between Pr55 Gag , PI(4,5)P 2 , and viral RNA at lipid rafts have been hypothesized to be important for the oligomerization of Pr55 Gag (Ono et al., 2007) . Viral envelope (Env) is then recruited to the lipid raft domains and actively packaged into newly forming virions, via an interaction between MA and the long cytoplasmic tail of the Env transmembrane subunit (gp41CT) (Bhattacharya et al., 2006) .
Structural analyses of MA demonstrate that the protein consists of five alpha-helical domains, four of which form an N-terminal globular domain capped by a mixed beta-sheet Massiah et al., 1996) . This beta-sheet region, in conjunction with the exposed myr group is thought to have direct contact with membranes. The C-terminal fifth helix extends away from the globular head. Both NMR and crystallographic studies support the notion that MA forms trimers in solution, but it is unclear whether MA remains a trimer when associated with virions . Recent NMR work suggests that MA forms a hexameric lattice on cholesterol-rich membranes, with trimerization occurring at the interface between three hexamer rings (Alfadhli et al., in press ). The gp41CT is thought to extend through the holes in the MA lattice.
In an attempt to further define regions in MA important for the regulation of viral entry we analyzed mutations in both the N-terminal basic domain and the C-terminal helix which have been previously proposed to affect replication at an early entry step (Casella et al., 1997; Yu et al., 1992) . Two deletion mutations in the C-terminus of MA, termed D9 and D10, were shown previously to affect the ability of virus to propagate in a T-cell line (Yu et al., 1992) . Mutation D9 contains a deletion of aa 105-114 and a Leu to Ile substitution at residue 104 while mutation D10 harbors a deletion of aa 116-123 ( Fig. 1) . Yu et al. (1992) determined that D9 and D10 did not affect assembly or later post-entry steps in viral replication, and suggested that these mutants are defective at the step of viral fusion.
We also considered two N-terminal basic domain mutations, MA (R18G,K20I,R22A) and MA (K32I,H33L), which are designated MA18,20,22 and MA32,33 ( Fig. 1 ). These mutants were previously shown to harbor an early entry defect in addition to displaying an impaired ability to incorporate envelope (Casella et al., 1997) .
Our results indicate that the C-terminal mutations only mildly affect infectivity and fusion, and these defects are attributable to corresponding reductions in envelope incorporation. In contrast, the N-terminal mutations induce severe impairments in infectivity, fusion, and envelope incorporation. Truncation of the gp41CT rescued the phenotype of one of the C-terminal deletions, but was unable to correct the defect resulting from the N-terminal mutations. Hill et al. (1996) .
Results

Characterization of infectivity defects induced by N-and C-terminal MA mutations
We chose to analyze four different MA mutants which were proposed in previous studies to be defective at an early entry step in viral replication (Casella et al., 1997; Yu et al., 1992) . Two mutations, MA18, 20, 22 and MA32, 33, are in the N-terminal globular head region, while D9 and D10 are 10 and 8 aa deletions in the extended C-terminal tail of MA, respectively. The mutations are shown schematically in relation to other known functional domains in MA ( Fig. 1A ). Molecular modeling of MA illustrates that these mutations represent two distinct domains of the MA protein (Figs. 1B and C) . It is interesting to note that the N-terminal MA mutations are located in the solvent-exposed β-sheet which contains the membrane-interacting basic domain (Freed et al., 1994; Hill et al., 1996; Massiah et al., 1996) .
In order to study these mutations, the mutant MA domains were subcloned into the p134 proviral backbone with an R5 Env, to insure that studies of infectivity, fusion, and envelope incorporation were performed in the context of the same Env and other viral proteins (Kaushik and Ratner, 2004) . Consistent with findings from previous reports, immunoprecipitation of virus pelleted through a 20% sucrose cushion with AIDS patient sera showed that Gag protein synthesis and processing were not significantly affected by the MA mutations (data not shown).
Viral replication was measured in a single-cycle assay, by infecting MAGI-5 cells with equal amounts of virus, as measured by p24 ELISA (Fig. 2 ). Infectivity of D9 and D10 was reduced to 35% and 25% of wild-type levels, respectively ( Fig. 2A ), but the infectivity of MA18,20,22 and MA32,33 were more severely affected ( Fig. 2B) . A virus, which harbors a Leu to Glu change in MA at position 12 (L12E), shown to be defective in packaging full-length envelope, was used as a negative control (Freed and Martin, 1996) . The level of L12E infectivity was reduced to approximately 10% of wild-type levels. The results from the N-terminal mutations are consistent with levels of infectivity measured in a similar assay (Casella et al., 1997) . However, our infectivity data for the D9 and D10 mutants differs from those previously reported (Yu et al., 1992) . That study showed that both C-terminal deletion mutants caused significant delays in a long-term replication assay in the Sup-T1 T-cell line. In addition, the phenotype of D10 was more severe than that of D9.
N and C-terminal mutants are defective in virus-dependent fusion
In order to test the hypothesis that the N-terminal and Cterminal mutations block replication at an early entry step, we analyzed the ability of these mutant viruses to induce fusion between cells expressing CD4 and CCR5 co-receptor. We employed a quantitative virus-dependent fusion assay to measure fusion by 134 wild-type virus, as well as by D10, MA 18,20,22, and MA 32,33 mutant viruses ( Fig. 3) (Pontow et al., 2004) . L12E virus and an envelope-deficient (Env-) virus were used as negative controls in these experiments. The fusion assays yielded results that are consistent with the MAGI-5 infectivity data. D10 induced approximately 50% of wild-type fusion levels ( Fig. 3A) , while levels of fusion induced by MA 18,20,22 and MA32,33 were reduced to 25% and 20% of wildtype levels, respectively ( Fig. 3B ).
In an effort to eliminate the possibility that the N-terminal mutations affected the intrinsic fusion activity of the viral envelope, we used an envelope-dependent cell-cell fusion assay to evaluate envelope protein function. Transfection of an Envproviral clone resulted in no detectable fusion activity. In contrast, the envelope-dependent fusion activity induced by MA18,20,22 and MA32,33 mutant proviruses was not significantly different from that induced by the WT proviral clone (data not shown).
C-terminal matrix mutants display mild defects in envelope incorporation
Various mutations in MA have been shown to abrogate the ability of newly assembled virions to incorporate viral envelope. This is one possible explanation for the fusion defects induced by the N-and C-terminal mutants. Although, the initial characterization of the D9 and D10 mutant viruses maintained that the levels of viral envelope incorporated were unaffected, the authors examined only the levels of envelope present in virus pelleted through a sucrose cushion (Yu et al., 1992) . For a more definitive assay, mature particles from metabolically labeled transfected 293T cells were harvested, pelleted through a sucrose cushion, and analyzed by centrifugation through a linear 20-60% sucrose density gradient. The radioactivity levels and densities of the gradient fractions are shown graphically in Fig. 4A . Mature particles have been shown to have a density of approximately 1.14-1.16 g/ml (Tang et al., 2003) .
Peak fractions with densities between 1.12 and 1.16 g/ml were collected and immunoprecipitated with pooled AIDS patient sera. The immunoprecipitated fractions were resolved by SDS-PAGE ( Fig. 4B ). While Gag synthesis and processing were found to be unaffected by the mutations, densitometric analysis of the gp120 (Env) to p24 (Gag) ratios in mutant compared to wild-type virions revealed that D9 and D10 have mild defects in Fig. 4 . C-terminal matrix mutants display mild defects in envelope incorporation. Metabolically-labeled virus produced from 134 (WT), D9 and D10 proviral clones was pelleted through a sucrose cushion, resuspended and centrifuged through 20-60% sucrose density gradients. (A) CPM of 1 ml sucrose gradient fractions 1-16, collected from top to bottom. The range of peak fraction densities is shown, as measured by refractometry. (B) SDS-PAGE analysis of viral proteins immunoprecipitated from peak fractions with pooled AIDS patient sera (numbered above each lane according to fraction number). Bands delineating p17 Matrix, p24 Capsid, and gp120 Env are shown. Sizes of molecular weight markers are shown to the left of the gel. (C) gp120:p24 ratios from peak fractions as calculated by densitometry are shown. envelope incorporation (Fig. 4C ). The quantitative defects in envelope incorporation of the C-terminal mutants were similar to the impairment of infectivity ( Fig. 2A) and fusion (Fig. 3A) .
N-terminal matrix mutants display severe defects in envelope incorporation
Sucrose density gradient analysis was used to examine the levels of homologous envelope in mature MA18,20,22 and MA32,33 mutant virions (Fig. 5A) . Gag processing was unaffected by the mutations (Fig. 5A) , however comparisons of gp120:p24 ratios demonstrated that the N-terminal mutations are severely impaired in their ability to incorporate envelope (Fig.  5B) . These results are consistent with envelope incorporation data presented previously (Casella et al., 1997) .
Truncation of gp41CT rescues infectivity of one C-terminal mutant, but not N-terminal MA mutations
Several lines of evidence suggest that an interaction between MA and gp41CT regulates viral fusion and envelope incorporation (Murakami et al., 2004; Wyma et al., 2004) . Truncation of the gp41CT has been shown to rescue the infectivity of virions harboring the L12E mutation in MA, which is known to abrogate envelope incorporation into viral particles. In addition, truncation of the cytoplasmic tail of gp41, in the context of uncleaved Gag restores the fusion defect exhibited by immature particles. We tested the hypothesis that altered MA-gp41 interactions are responsible for the N-and C-terminal MA mutant phenotypes by introducing a stop codon into the gp41 coding sequence such that the C-terminal 144 aa of gp41 are not translated. We then examined the effects of this truncation (gp41 CTD) on viral infectivity (Fig. 2) . Our results demonstrate that D10CTD rescues infectivity of D10, whereas D9CTD does not ( Fig. 2A ). Truncation of gp41CT was unable to rescue the infectivity defect induced by the MA18,20,22 and MA32,33 mutations (Fig. 2B) .
Virus-dependent fusion assays were also performed with CTD mutants of MA18,20,22 and MA32,33 (Fig. 3B) . Compared to MA18,20,22 and MA32,33, the CTD mutants increased virus-dependent fusion activity 2.9-fold and 3.7-fold, respectively, based on four independent experiments (two tailed t test p b 0.001). In each case, truncation of gp41 rescued the defect in virus-dependent fusion activity. This suggests that the defect in gp120 incorporation in MA18,20,22 and MA32,33 viruses was overcome by truncation of gp41. Moreover, it suggests that defects in infectivity of the CTD mutants are due to a post-fusion event.
Discussion
HIV-1 MA is involved in many processes relating to both entry and assembly of the virus (Bukrinskaya, 2004; Freed, 1998; Scarlata and Carter, 2003) . Recently MA has been proposed to have an inhibitory function in relation to HIV-1 fusion, especially in the context of immature virions (Murakami et al., 2004; Wyma et al., 2004) . Our studies attempt to further explore the role of MA in the regulation of viral entry and fusion.
In an effort to define potential fusion regulatory domains in MA, we analyzed mutations that have been hypothesized to block replication at an entry step.
Deletion mutations in the C-terminus of MA, D9 and D10, were shown previously to severely affect the ability of virus to propagate in a T-cell line (Yu et al., 1992) . The replication defect demonstrated by D9 mutant virus was less severe than that of D10 mutant virus, but a delay in replication was still appreciated. Analysis of the assembly stages of HIV-1 replication suggested that these mutants did not affect the viral synthesis of Gag, proteolytic cleavage of Gag, or assembly and release of virus. Fig. 5 . N-terminal MA mutants display severe defects in envelope incorporation. Metabolically-labeled virus produced from 134 (WT), MA18,20,22, MA32,33 and envelope deficient (Env-) proviral clones was pelleted through a sucrose cushion, resuspended and centrifuged through 20-60% sucrose density gradients. (A) Immunoprecipitation of peak fractions was performed with AIDS patient sera. Lane numbers correspond to gradient fraction numbers. (B) gp120:p24 ratio calculated by densitometry.
Our results differ from some of the previous conclusions regarding the D9 and D10 mutations (Yu et al., 1992) . A single cycle infectivity assay suggests that while both D9 and D10 are replication deficient, the defects were relatively mild. Both D9 and D10 exhibited three to four-fold reductions in infectivity ( Fig. 2A) . Furthermore, studies of mature virions indicate that the assembly of the mutant virions is affected by the C-terminal deletions in MA. Sucrose density gradient analysis and immunoprecipitation with AIDS patient antisera indicate that Gag protein synthesis and processing appear to be unaffected, but envelope incorporation is reduced (Figs. 4B and C) .
Data from Yu et al. (1992) showed that the C-terminal mutations did not affect later post-entry steps in the viral life cycle such as DNA synthesis. Thus, it was hypothesized that D9 and D10 affected an early entry step in viral replication. Interestingly, a sequence, AADTGHSSQV, deleted in mutant D10, is highly conserved among HIV-1 strains and exhibits high homology to sequences in VP1 of picornaviridae which have been implicated in poliovirus penetration of host cells (Fricks and Hogle, 1990) . Virus-dependent fusion assays demonstrate a defect induced by the D9 and D10 mutations (Fig. 3A ), but this fusion defect correlates well with the reduced levels of envelope incorporated into the mutant virions (Fig. 4C) .
The basic residues in the solvent exposed side of the Nterminal MA β-sheet also appear to play a role in HIV entry. During their initial characterization, both the MA18,20,22 and MA32,33 exhibited severely reduced infectivity, reduced expression of intracellular viral proteins and only mild defects in Gag processing (Casella et al., 1997) . In addition, the mutant viruses were unable to reverse-transcribe their RNA, suggesting that there was a defect in an early replication step, prior to synthesis of DNA. Interestingly, these mutants were also defective in HIV Env incorporation into the virions.
Our results confirmed the severe replication block induced by the N-terminal mutations (Fig. 2B) . These viruses were also unable to induce fusion ( Fig. 3B ) and sucrose density gradient analysis confirms that both MA18,20,22 and MA32,33 are defective in envelope incorporation (Fig. 5 ). Despite the inability of the N-terminal mutations to incorporate HIV-1 envelope, Casella et al. (1997) determined that these mutants could still incorporate a heterologous retroviral envelope glycoprotein from amphotropic murine leukemia virus (Casella et al., 1997) . However, these pseudotyped viruses were still replication deficient, suggesting that the entry defect is not solely related to the HIV MA and HIV Env interaction. Interestingly, while truncation of the gp41CT rescues the fusion defects induced by the N-terminal mutations (Fig. 3B) , thus demonstrating restoration of Env to the surface of the virions, the CTD mutation cannot rescue the defect in infectivity (Fig. 2B) . Data from our lab and from other studies of HIV-1 and SIV envelope suggest that envelope with truncated cytoplasmic tails is incorporated by a passive packaging mechanism independent of MA interaction with Env (Guern and Levy, 1992; Johnston et al., 1993; Salzwedel et al., 1993; Sauter et al., 1996) . Since envelope incorporation is restored, but the replication defect persists, this would suggest that an additional post-entry defect is partly responsible for the N-terminal MA mutant replication block.
Taken together, the data presented in this report reveal that the major replication block for both the N-terminal and C-terminal mutations is during envelope incorporation, rather than at an early entry step.
It is likely that the D9 and D10 mutations affect the ability of Pr55 Gag to interact directly with gp41CT or with an additional host bridging molecule. The large deletions in the extended 5th helix may alter the conformation of the Pr55 Gag precursor and impair protein-protein interactions. It is also possible that these mutations affect the ability of Pr55 Gag to oligomerize at the membrane. This scenario also applies to the N-terminal mutations, but it is appealing to consider other mechanisms by which mutations in the basic domain impair envelope incorporation. There is strong evidence to support a role for the basic domain in membrane binding to acidic phospholipids and neutralization of the charge in this domain may inhibit membrane adherence by Pr55 Gag , and inhibit assembly (Freed et al., 1994 Ono et al., 2000; Scarlata et al., 1998) . Additionally, there is good evidence to implicate the basic domain of MA in the interaction with the lipid raft associated PI (4,5)P2 (Ono et al., 2004; Saad et al., 2006) . This interaction has been shown to aid in targeting Pr55 Gag to lipid raft domains and, importantly, to mediate the myristyl switch which exposes the myr group and anchors Pr55 Gag into the membrane. NMR studies demonstrate that PI(4,5)P 2 interacts directly with the basic patch in MA. Interestingly, NMR and mass spectroscopic footprinting studies have suggested that MA residues 32 and 33 are important in mediating the interaction between MA and PI (4,5)P 2 . Hence, it is possible that the N-terminal mutations in Gag affect the ability of Pr55 Gag to target to the plasma membrane and associate with PI(4,5)P 2 at rafts. This could impair the myristyl switch, prevent adequate oligomerization, and potentially redirect Gag to other intracellular compartments, all of which adversely impact envelope incorporation. Future studies will attempt to further define the entry block exhibited by the N-terminal MA mutations and elucidate the mechanism by which diverse mutations in MA affect envelope incorporation.
Materials and methods
Plasmids
The GB107, an envelope deficient proviral clone and molecular clones harboring the MA18,20,22 and MA32,33 mutations within the GB107 backbone were the kind gifts of A. Panganiban (Buchscacher and Panganiban, 1992; Casella et al., 1997) . P. Spearman kindly donated plasmids containing the D9 and D10 MA mutations in the HXB2R3 proviral background. The mutant matrix regions were PCR-amplified from the proviral DNAs using standard techniques. Specifically, we amplified a region of gag extending from the BssHII to SphI restriction sites which includes the MA coding region. The PCR products were TA cloned into the pGEMT-easy vector (Promega) and the BssHII-SphI gag fragments were subsequently excised by restriction digestion. The mutant gag cassettes were subcloned into p134, an NL4-3 proviral clone backbone including gag derived from X4-strain HXB2 and env derived from R5-strain YU2, as described previously (Kaushik and Ratner, 2004) . Envelope glycoprotein gp41 C-terminal deletion (CTD) mutants were generated by introducing a stop codon to produce TM lacking the C-terminal 144 amino acids Murakami et al., 2004; Wyma et al., 2004) . The BssHII-SphI gag fragment of gp41-CTD was substituted with the gag cassettes of MA18, 20, 22, MA32, 33, D9, or D10 .
Cell culture and transfection
Proviral clones were transfected into 293T cells with TransIT-LT1 (Mirus) according to the manufacturer's protocol. 293T cells were maintained in DMEM supplemented with 10% Fetal-Clone III (Gibco), 4 mM L-glutamine, and penicillin-streptomycin. MAGI-5 reporter cells were maintained in supplemented DMEM with puromycin, hygromycin, and G418 (Pirounaki et al., 2000) . U87 (CD4+, R5+) were maintained in DMEM supplemented with 10% Fetal-Clone III, 4 mM L-glutamine, penicillin-streptomycin, puromycin and G418 (Pontow et al., 2004) .
Western blotting and immunoprecipitation
HIV-1 proteins were immunoprecipitated and detected by western blot using pooled HIV-1 patient sera. Anti-p17 and anti-p24 polyclonal rabbit antisera were also used in western blot assays (Spearman et al., 1994) .
Infectivity assay
MAGI-5 cell lines (HeLa β-galactosidase+, CD4+, CCR5+) were plated in a 96 well plate at a density of 10 4 cells per well. The cells were then infected with 25 ng, as determined by p24 ELISA (Beckman-Coulter, Fullerton, CA), of virus in triplicate. Virus was removed 40 h post-infection and the cells were then fixed with PBS containing 2% formaldehyde (Sigma, St. Louis, MO) and 0.2% glutaraldehyde (Sigma, St. Louis, MO) for 5 min at room temperature. Cells were washed in PBS and stained with X-gal (Calbiochem San Diego, CA) for 35 to 55 min at 37°C. Cells were then washed again and the number of blue cells per well was counted.
Virus-dependent fusion assay
The virus-dependent fusion assay was performed as described previously (Pontow et al., 2004) . Briefly, equivalent amounts of virus particles as determined by p24 antigen ELISA (Beckman-Coulter, Fullerton, CA) were mixed at 37°C with U87 glioma cells expressing CD4 and a CCR5-GFP fusion protein. U87.CD4.CCR5.GFP cells were serum-starved for 24 h and then they were infected with recombinant vaccinia virus with β-galactosidase under the control of the T7 promoter (vCB21R), or recombinant vaccinia virus expressing T7 polymerase (vPT7-3). Cells were infected overnight, harvested by trypsin treatment, resuspended in HBSS with 3% fetal calf serum, and mixed (1:1) in triplicate wells of a 96-well plate, and then virus and 20 μg/ml DEAE-dextran were added. Fusion reactions were incubated for 3 h at 37°C. Fusion was stopped by the addition of NP-40 to a final concentration of 1% and βgalactosidase activity was determined using chlorophenol redβ-D-galactopyranoside (Calbiochem, San Diego, CA) as substrate, and reading the absorbance at 579 nm.
Envelope-dependent fusion assay
WT and mutant proviral clones were transfected into BSC40 cells. After 24 h, these cells were infected with vPT7-3. An equal number of U87.CD4.CCR5.GFP cells were infected with vCB21R. Cells were cultured overnight, harvested by trypsin treatment, washed and mixed in triplicate wells of a 96-well plate. Cell-cell fusion reactions were incubated for 3 h at 37°C, and β-galactosidase activity in cell lysates determined.
HIV-1 sucrose gradient analysis
293T cells plated in 100 mm dishes were transfected with 10 μg of proviral DNA using TransIT (Mirus) transfection reagent as described in the manufacturer's protocol. Transfection media was removed 1 day following transfection and the cells were then metabolically labeled with 200 μl of 35-S Translabel (MPbio) in cys(−)/met(−) DMEM supplemented with 10% dialyzed fetal calf serum (Washington University Tissue Culture Center). Supernatants containing radio-labeled virus were then harvested 48-60 h later. The viral supernatants were subsequently cleared of cellular debris by centrifugation for 5 min at low speed. Viruses were pelleted through a 20% sucrose cushion via ultracentrifugation at 45000 rpm for 45 min in an SW55Ti rotor (Beckman). The pelleted virus was then resuspended in 700 μl of OptiMEM (Invitrogen) and gently layered at the top of a 16 ml 20-60% sucrose gradient. The gradient was then centrifuged at 26000 rpm in an SW28 rotor (Beckman) for 24 h, and 1 ml fractions were collected from the top of the gradient. The gradient fractions were analyzed using a refractometer (Fisher Scientific Co.) and radioactivity quantified using a scintillation counter (Beckman-Coulter). The density of each fraction was calculated using the formula ρ = 2.6496 η − 2.5323, where ρ is density (g/ml) and η is the refractive index (Forshey et al., 2002; Tang et al., 2003) . Peak fractions with densities greater than 1.12 g/ml but less than 1.16 g/ml were then immunoprecipitated overnight with pooled AIDS patient sera at 1:100 dilution. Immunoprecipitated samples were then resolved by electrophoresis through a 15% SDS-PAGE gel. The gel was subsequently fixed, dried, and exposed to a phosphoimager screen for 24 h. The screen was then analyzed by the STORM phosphoimager system and quantified using MacQuant imaging software.
